10-Q: Century Therapeutics Extends Runway, Reprioritizes Pipeline

Century Therapeutics reports a nine-month net income driven by a collaboration termination, extends its cash runway into Q4 2027, and reprioritizes its cell therapy pipeline.

Summary

• Achieved a net income of $9.591 million for the nine months ended September 30, 2025, a significant improvement from a $90.493 million net loss in the prior year, primarily due to $109.164 million in collaboration revenue recognized from the termination of the Bristol-Myers Squibb agreement.
• Incurred a net loss of $34.422 million for the three months ended September 30, 2025, compared to a net loss of $31.226 million for the same period in 2024.
• Cash, cash equivalents, and investments totaled $132.748 million as of September 30, 2025, with management believing these resources are sufficient to fund operations into the fourth quarter of 2027.
• Research and development (R&D) expenses decreased to $75.972 million for the nine months ended September 30, 2025, from $77.869 million in 2024, mainly due to a reduction in R&D staff and the completion of a manufacturing campaign.
• General and administrative (G&A) expenses decreased to $23.047 million for the nine months ended September 30, 2025, from $25.400 million in 2024.
• Recorded an impairment charge of $6.763 million on long-lived assets, specifically a portion of the Philadelphia headquarters, following a reduction in force and plans to sublease.
• Completed a reduction in force (RIF) in July 2025, reducing its workforce by approximately 51% as part of a broader effort to focus on key programs.
• Prioritized clinical development for CNTY-101, a CAR-iNK cell therapy, in the CARAMEL Phase 1/2 investigator-sponsored trial (IST) for B-cell-mediated autoimmune diseases, discontinuing company-sponsored CALiPSO-1 trial activities.
• Advancing CNTY-813, a beta islet program for Type 1 diabetes, towards IND-enabling studies by the end of 2025, with an IND submission anticipated as early as 2026.
• Progressing IND-enabling studies for CNTY-308, a CD19-targeted ab CAR-iT cell therapy for B-cell-mediated diseases, with clinical studies expected to initiate in 2026.

Sentiment

Score: 6

Explanation: While the company reported a net income for the nine-month period and extended its cash runway, these positives are largely driven by a one-time revenue recognition from a terminated collaboration and a significant workforce reduction. The underlying operational losses persist, and future capital raises are anticipated. The strategic focus on key pipeline assets is a positive, but the overall financial health remains challenging for an early-stage biotech.

Positives

• Achieved a net income of $9.591 million for the nine months ended September 30, 2025, a significant improvement from a $90.493 million net loss in the prior year, primarily due to the recognition of $109.164 million in collaboration revenue from the terminated Bristol-Myers Squibb agreement.
• Extended cash runway into the fourth quarter of 2027, providing longer financial stability for ongoing operations and pipeline development.
• Strategic reprioritization of the pipeline, focusing resources on high-potential programs like CNTY-101 (CARAMEL IST), CNTY-813 (Type 1 diabetes), and CNTY-308 (B-cell-mediated diseases).
• Anticipated initial data presentation for CNTY-101 in the CARAMEL IST in December 2025, which could provide early clinical validation.
• Advancement of CNTY-813 into IND-enabling studies by the end of 2025 and CNTY-308 into clinical studies in 2026, indicating pipeline progression.

Negatives

• Incurred a net loss of $34.422 million for the three months ended September 30, 2025, an increase from the $31.226 million net loss in the same period of 2024.
• The collaboration agreement with Bristol-Myers Squibb was terminated, eliminating a significant source of future collaboration revenue.
• Completed a reduction in force (RIF) of approximately 51% of the workforce in July 2025, indicating significant operational restructuring and potential impact on morale and future capabilities.
• Recorded an impairment charge of $6.763 million on long-lived assets, specifically a portion of the Philadelphia headquarters, reflecting a decrease in asset value due to changes in strategy (subleasing).
• Cash and cash equivalents decreased from $58.441 million at December 31, 2024, to $55.515 million at September 30, 2025.
• Short-term investments decreased significantly from $130.851 million at December 31, 2024, to $77.234 million at September 30, 2025.
• Discontinued company-sponsored clinical activities for the CALiPSO-1 trial, redirecting resources, which might be perceived as a setback for that specific program.

Risks

• Ability to raise additional capital to fund operations and continue product candidate development.
• Uncertainty of successfully advancing current and future product candidates through preclinical studies and clinical trials.
• Ability to generate revenue from future product sales and achieve and maintain profitability.
• Challenges due to the novel nature of iPSC-derived immuno-oncology and autoimmune treatments.
• Success of competing therapies that are or may become available.
• Reliance on the maintenance of the collaborative relationship with FUJIFILM Cellular Dynamics Inc. (FCDI) for access to key differentiation and reprogramming technology.
• Timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval of product candidates.
• Ability to successfully manufacture certain product candidates, and the timing and costs of such manufacturing activities.
• Performance of third parties in connection with the development of product candidates, including clinical trial conductors and third-party suppliers/manufacturers.
• Ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise.
• Public opinion and scrutiny of cell-based immuno-oncology and autoimmune and inflammatory therapies and its potential impact.
• Ability to successfully commercialize product candidates and develop sales and marketing capabilities, if approved.
• Volatility of capital markets and other macroeconomic factors, including inflationary pressures, trade disputes, banking instability, global health crises, and geopolitical tensions.
• Ability to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting product candidates, and to commercialize without infringing third-party rights.
• Ability to recruit and retain key members of management and other clinical and scientific personnel.

Future Outlook

The company expects to incur additional losses in the future to fund its operations and conduct product research and preclinical and clinical development. Expenses and operating losses are anticipated to increase substantially over the foreseeable future due to advancing iPSC cell therapy platforms, progressing preclinical and clinical development, seeking regulatory approvals, expanding cGMP facilities, maintaining intellectual property, and increasing employee headcount. Existing cash, cash equivalents, and investments are believed to be sufficient to fund operating expenses and capital expenditures requirements into the fourth quarter of 2027. However, the company anticipates needing to raise additional financing in the future to fund operations, including the commercialization of any approved product candidates. Key pipeline milestones include moving CNTY-813 into IND-enabling studies by the end of 2025 with an IND submission anticipated as early as 2026, initiating clinical studies for CNTY-308 in 2026, and expecting initial data presentation for CNTY-101 in the CARAMEL IST in December 2025.

Management Comments

• "We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases and cancer."
• "What we believe further sets us apart from other allogeneic approaches is our focus on induced pluripotent stem cells, or iPSCs, which possess the unique ability to self-renew indefinitely and differentiate into any cell type, enabling virtually unlimited genetic editing, consistent reproducibility, and scalable manufacturing."
• "Our vision is to become a premier, fully integrated biotechnology company by developing and ultimately commercializing off-the-shelf allogeneic cell therapies that dramatically and positively transform the lives of patients suffering from life-threatening autoimmune diseases and cancers."
• "Based on our current business plans, we believe our cash, cash equivalents and investments as of September 30, 2025, will be sufficient for us to fund our operating expenses and capital expenditures requirements into the fourth quarter of 2027."
• "We anticipate that we will need to raise additional financing in the future to fund our operations, including funding for preclinical studies, clinical trials and the commercialization of any approved product candidates."

Industry Context

The company operates in the highly innovative and competitive field of allogeneic cell therapies, specifically leveraging induced pluripotent stem cells (iPSCs) for immuno-oncology and autoimmune diseases. This approach aims to overcome limitations of autologous therapies by providing "off-the-shelf" treatments. The termination of the Bristol-Myers Squibb collaboration highlights the inherent risks and portfolio prioritization common in large pharmaceutical partnerships within the biotech sector. The strategic shift towards prioritizing specific clinical programs (CNTY-101, CNTY-813, CNTY-308) and a significant reduction in force reflects a common industry trend for early-stage biotech companies to streamline operations and focus resources on their most promising assets to extend cash runways and achieve critical milestones. The development of a beta islet program for Type 1 diabetes indicates an expansion into new therapeutic areas beyond oncology, aligning with broader industry interest in regenerative medicine and autoimmune disease treatments.

Comparison to Industry Standards

• The company's focus on iPSC-derived allogeneic cell therapies positions it in a cutting-edge segment of the biotech industry, aiming to differentiate from first-generation autologous cell therapies (e.g., Novartis' Kymriah, Gilead's Yescarta) by offering scalability and broader patient access.
• The strategic reprioritization and workforce reduction are common actions for early-stage biotech companies facing significant R&D costs and the need to extend financial runways, similar to moves seen from other development-stage biotechs adjusting to market conditions and clinical trial progress.
• The termination of the Bristol-Myers Squibb collaboration, while a financial hit, is not uncommon in the volatile landscape of pharmaceutical partnerships, where large companies frequently re-evaluate pipelines and strategic fit.
• The cash runway into Q4 2027, following a significant restructuring, is a positive indicator for an early-stage biotech, providing a relatively long period to achieve clinical milestones before needing to raise additional capital, which is often a challenge for companies without commercial products.
• The advancement of multiple preclinical and early clinical programs (CNTY-813, CNTY-308, CNTY-101) is typical for a company at this stage, demonstrating active pipeline development, though the high failure rate in clinical trials remains an industry-wide challenge.

Legal Proceedings

• Management believes there are currently no claims or actions pending against the company that would have a material adverse effect on its results of operations, financial condition, or cash flows.

Related Party Transactions

• **FUJIFILM Cellular Dynamics, Inc. (FCDI)**: FCDI is a shareholder and a key collaborator. The company holds non-exclusive Reprogramming License and exclusive Differentiation License agreements with FCDI for iPSC-related patents and know-how. A Master Collaboration Agreement with FCDI for services to develop and manufacture iPSCs and immune cells was extended through September 30, 2025. A Manufacturing Agreement with FCDI covers technology transfer, process development, analytical testing, and cGMP manufacturing services. The company paid FCDI an upfront payment of $10 million and will pay percentages of certain milestone and royalty payments related to Japan under the now-terminated Bristol-Myers Squibb Collaboration Agreement. In September 2023, the company entered into an Autoimmune License with FCDI for iPSC-derived therapies for inflammatory and autoimmune diseases, with FCDI eligible for development/regulatory milestone payments and low single-digit royalties. Payments to FCDI were $9 thousand and $1,924 thousand, and R&D expenses incurred were $12 thousand and $1,891 thousand for the three and nine months ended September 30, 2025, respectively.
• **Bayer Health, LLC (Bayer)**: Bayer has a right of first refusal to acquire certain products (up to four) researched and developed by the company, exercisable in a non-sequential and alternating manner, subject to additional limitations.

Stakeholder Impact

• **Shareholders**: Potential for dilution from anticipated future capital raises; positive impact from extended cash runway and strategic pipeline focus; negative impact from workforce reduction and asset impairment.
• **Employees**: Significant impact from the 51% reduction in force in July 2025; remaining employees may experience changes in roles and responsibilities due to strategic reprioritization.
• **Customers/Patients**: Potential for new therapies in autoimmune diseases and cancer if pipeline candidates succeed; discontinuation of CALiPSO-1 trial may affect patients in that specific study.
• **Creditors**: Extended cash runway provides more confidence in short-to-medium term liquidity.
• **Suppliers/Partners**: Termination of Bristol-Myers Squibb collaboration impacts that specific partnership; ongoing collaboration with FCDI continues.

Next Steps

• Move CNTY-813 into IND-enabling studies by the end of 2025.
• Anticipate IND submission for CNTY-813 as early as 2026.
• Initiate clinical studies for CNTY-308 in 2026.
• Investigators of the CARAMEL IST for CNTY-101 are expected to present initial data in December 2025.
• Continue to advance iPSC cell therapy platforms.
• Progress preclinical and clinical development of product candidates.
• Seek to discover and develop additional product candidates.
• Expand and validate own clinical-scale cGMP facilities.
• Seek regulatory approvals for product candidates.
• Maintain, expand, protect, and enforce intellectual property portfolio.
• Acquire or in-license other product candidates and technologies.
• Increase employee headcount and related expenses to support activities.

Key Dates

Recommendation

The company has undertaken significant strategic restructuring, including a major workforce reduction and pipeline reprioritization, to extend its cash runway into Q4 2027. While the nine-month period shows a net income, this is primarily due to a one-time revenue recognition from a terminated collaboration, and operational losses persist. The focus on high-potential iPSC-derived cell therapies for autoimmune diseases and Type 1 diabetes, alongside the CARAMEL IST data expected in December 2025, offers future upside. However, the early stage of development for most programs, the inherent risks of clinical trials, the need for future capital raises, and the recent operational challenges suggest a "hold" position until more definitive clinical data and a clearer path to profitability emerge. The stock is speculative, but the extended runway provides time for the strategy to play out.

Keywords

Cell therapy, iPSC, Immuno-oncology, Autoimmune diseases, Natural Killer cells, T cells, CAR-iT, CAR-iNK, Type 1 Diabetes, CNTY-813, CNTY-308, CNTY-101, Biotechnology, Clinical trials, Preclinical development, Allogeneic, Gene editing, Allo-Evasion, SEC filing, 10-Q